Publications by authors named "F Gastaldon"
Article Synopsis
- - The Renal Biopsy for Kidney Transplantation Therapy (ReBIrth) meeting held on May 31, 2022, in Bologna, Italy, focused on advancements in kidney transplantation, bringing together key experts in nephrology, surgery, and pathology.
- - The paper highlights experiences with kidney transplants and aims to report on the histopathological features of failed kidney allografts, analyzed through a digital pathology platform.
- - Findings suggest that digital pathology effectively identifies critical morphological and immunohistochemical traits, potentially enhancing the use of immunosuppressive therapy to reduce graft failure and improve patient care.
Objectives: The study aim was to assess predictors of negative antibody response (AbR) in solid organ transplant (SOT) recipients after the first booster of SARS-CoV-2 vaccination.
Methods: Solid organ transplant recipients receiving SARS-CoV-2 vaccination were prospectively enrolled (March 2021-January 2022) at six hospitals in Italy and Spain. AbR was assessed at first dose (t), second dose (t), 3 ± 1 month (t), and 1 month after third dose (t).
Article Synopsis
- * Antibody levels in SOT recipients increased significantly within the first 76 days but showed a non-significant decrease after 118 days, while HCWs experienced a notable decrease in antibody levels over the same periods.
- * Factors such as liver transplant type, time since SOT, specific mRNA vaccine used, and certain medications were linked to a better antibody response; meanwhile, older age and
Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary kidney disease, responsible for 10% of patients on renal replacement therapy. The disease is well known to be associated with many extrarenal manifestations. Leukopenia may also be present, even if it is not commonly identified as a typical extrarenal manifestation.
View Article and Find Full Text PDFAutosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary kidney disease and accounts for∼10% of patients on renal replacement therapy. In the last decade, no specific treatment was available and only preventive measures could be put in place to delay the onset of ESRD. Following the results of the TEMPO 3:4 study, tolvaptan was approved in many countries, for the purpose of slowing the progression of renal insufficiency.
View Article and Find Full Text PDF